Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Liabilities: 2022-2024

Historic Other Non-Current Liabilities for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $2.5 million.

  • Stoke Therapeutics' Other Non-Current Liabilities fell 38.56% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 38.56%. This contributed to the annual value of $2.5 million for FY2024, which is 49.26% down from last year.
  • Stoke Therapeutics' Other Non-Current Liabilities amounted to $2.5 million in FY2024, which was down 49.26% from $4.9 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Other Non-Current Liabilities ranged from a high of $4.9 million in FY2023 and a low of $2.5 million during FY2024.
  • In the last 3 years, Stoke Therapeutics' Other Non-Current Liabilities had a median value of $3.0 million in 2022 and averaged $3.4 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 64.56% in 2023, then slumped by 49.26% in 2024.
  • Yearly analysis of 3 years shows Stoke Therapeutics' Other Non-Current Liabilities stood at $3.0 million in 2022, then skyrocketed by 64.56% to $4.9 million in 2023, then plummeted by 49.26% to $2.5 million in 2024.